Altogether, these data suggest that the knockdown of TRAIL-R2 restrains progression of small metastatic lesions in the liver and suppresses tumor cell proliferation, thereby reducing outgrowth of visible macroscopic metastases after surgery. This evidence concerns the gene TNFRSF10B and neoplasm.